Search

Objectives: This study aims to evaluate the prognostic significance of maximum standardized uptake value (SUVmax) on 18F-fluoro-2-deoxyglucose positron emission tomography/computed tomography (18FDG-PET/CT) for bone sarcoma., Patients and Methods: We retrospectively evaluated 34 patients (24 males, 10 females; mean age 36.6±24.2 years; range, 5 to 77 years) with pathologically proven bone sarcoma who underwent 18FDG-PET/CT for initial staging between September 2013 and September 2017. SUVmax of primary lesions were measured. Cumulative survival rate was calculated to evaluate the prognostic value of 18FDG-PET/CT findings. Survival duration was defined as the elapsed duration from the date of pre-treatment 18FDG-PET/CT scanning until the date of the final examination before the date of death., Results: The cut-off value for SUVmax in the definition of progression was 8. Mean SUVmax of the progressive group was statistically significantly higher than the non-progressive group. Distant metastases were present in 14 (41.1%) cases. Mortality and cumulative survival rates were 14.7% and 79.1±0.08%, respectively., Conclusion: Semiquantitative estimation of primary tumor metabolic activity in terms of baseline SUVmax using 18FDG-PET/CT can predict the overall survival of patients with bone sarcoma.

Purpose: The aim of the current study was to determine the diagnostic accuracy of whole-body 18F-fluoro-2-deoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in detecting carcinoma of unknown primary (CUP)., Materials and Methods: A total of 7,636 patients were investigated by FDG-PET/CT examinations at our Institution. We retrospectively evaluated the file records of 432 patients who were referred to FDG PET/CT imaging with a diagnosis of cancer of unknown primary, and included 316 of the patients with histopathologic verification at the final diagnosis. The sensitivity, specificity, positive predictive value, negative predictive value and accuracy were calculated. The Kaplan-Meier test was used for survival analysis. Median survival rate was calculated to evaluate the prognostic value of the FDG-PET/ CT findings., Results: In the search for a primary, FDG-PET/CT findings correctly diagnosed lesions as the site of the primary true positive in 238 cases, 10 findings diagnosed no site of a primary and none was subsequently proven true negative, 12 diagnoses were false positive and 56 were false negative. The sensitivity of FDG-PET/CT is 81% and the specificity 45%. Positive predictive value, negative predictive value and diagnostic accuracy were 95%, 15% and 78%, respectively., Conclusions: Whole-body FDG-PET/CT imaging is proven to be useful method in the search for the primary focus and metastases in patients with cancer of unknown primary.